A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults

NCT04380701 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Respiratory
Virus Diseases
Infection Viral
Vaccine Adverse Reaction
RNA Virus Infections
Protection Against COVID-19 and Infections With SARS CoV 2

Interventions

BIOLOGICAL: BNT162a1
BIOLOGICAL: BNT162b1
BIOLOGICAL: BNT162b2
BIOLOGICAL: BNT162c2

Sponsor

BioNTech SE